Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) have earned an average recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have given a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $6.8333.

A number of research firms have recently weighed in on PYXS. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price objective on shares of Pyxis Oncology in a research report on Tuesday, March 24th. Weiss Ratings lowered Pyxis Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, May 21st. Wall Street Zen lowered Pyxis Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Stifel Nicolaus cut their price objective on Pyxis Oncology from $9.00 to $8.00 and set a “buy” rating on the stock in a research report on Tuesday, March 24th. Finally, Wedbush began coverage on Pyxis Oncology in a research report on Tuesday, May 5th. They set an “outperform” rating and a $6.00 price objective on the stock.

Institutional Trading of Pyxis Oncology

Hedge funds and other institutional investors have recently bought and sold shares of the business. Atle Fund Management AB acquired a new stake in Pyxis Oncology in the fourth quarter valued at $710,000. Avanza Fonder AB acquired a new stake in Pyxis Oncology in the fourth quarter valued at $31,000. Persistent Asset Partners Ltd acquired a new stake in Pyxis Oncology in the third quarter valued at $77,000. Velan Capital Investment Management LP raised its stake in Pyxis Oncology by 37.5% in the third quarter. Velan Capital Investment Management LP now owns 55,000 shares of the company’s stock valued at $122,000 after buying an additional 15,000 shares in the last quarter. Finally, Qube Research & Technologies Ltd raised its stake in Pyxis Oncology by 128.4% in the second quarter. Qube Research & Technologies Ltd now owns 103,063 shares of the company’s stock valued at $113,000 after buying an additional 57,935 shares in the last quarter. 39.07% of the stock is currently owned by institutional investors and hedge funds.

Pyxis Oncology Stock Up 4.1%

NASDAQ:PYXS opened at $1.78 on Monday. Pyxis Oncology has a 52 week low of $0.97 and a 52 week high of $5.55. The stock’s fifty day moving average is $1.82 and its two-hundred day moving average is $2.08. The stock has a market capitalization of $112.76 million, a price-to-earnings ratio of -1.36 and a beta of 1.42.

Pyxis Oncology (NASDAQ:PYXS) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). On average, sell-side analysts expect that Pyxis Oncology will post -1.23 EPS for the current fiscal year.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical?stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody?drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off?target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early?stage ADC candidates directed against a variety of solid tumor antigens.